The gene behind the protection
The gene in question is a naked mole-rat variant of hyaluronan synthase 2, abbreviated nmrHas2. Hyaluronan (HA) is a long sugar polymer found throughout connective tissue, skin, and joints in most mammals. It is already familiar in medicine: doctors inject it into arthritic knees, and it is a key ingredient in dermal fillers. But in naked mole rats, HA appears in unusually large and abundant forms that do something extra. It actively suppresses uncontrolled cell growth. The backstory traces to a 2013 discovery published in Nature by Xiao Tian, Vera Gorbunova, Andrei Seluanov, and colleagues at Rochester. That study showed naked mole-rat cells secrete massive quantities of high-molecular-mass HA, and that this molecule is central to the animals’ near-total resistance to cancer. In captive colonies studied over decades, cancer incidence in naked mole rats falls below 1%, a figure that has no parallel among rodents. The 2013 paper pinpointed altered activity in two genes, HAS2 and HYAL2, as the molecular basis for that protection. Separate measurements published in Scientific Reports later confirmed the scale of the difference: naked mole-rat tissues and plasma contain roughly an order of magnitude more hyaluronan than those of mice. The gap is especially pronounced in skin and brain tissue.What the transgenic mice showed
Gorbunova and Seluanov’s team created transgenic mice engineered to overexpress the nmrHas2 gene. According to the Nature paper, these mice showed increased hyaluronan across multiple tissues, reduced rates of spontaneous cancer, and measurably improved healthspan. That last term is specific: it means the animals maintained physical function, lower frailty scores, and better overall condition deeper into old age compared with control mice. The benefits were not limited to cancer. A related line of research tested whether the same type of high-molecular-weight HA could fight chronic inflammation. In a 2023 study published in Cell Reports, Zhang et al. used engineered cells carrying naked mole-rat HAS2 to produce large HA molecules, then administered them to mice with chemically induced intestinal inflammation (a standard colitis model). The HA protected the animals’ gut lining. That result matters because chronic inflammation is one of the primary drivers of age-related disease in humans, from cardiovascular problems to neurodegeneration. Additional work by Gorbunova, Seluanov, and colleagues, published in 2020 in Nature Communications, found that very-high-molecular-mass HA activates signaling pathways tied to the tumor-suppressor protein p53 and broader cytoprotection. The molecule appears to do more than physically shield cells; it triggers internal stress-resistance programs.Where the science hits its limits
The leap from engineered mice to anything resembling a human therapy remains enormous. As of June 2026, no primary data exist from human cell lines or primate models testing nmrHas2 overexpression. No human trial timelines have been announced. The transgenic mouse results are striking, but long-term follow-up data beyond the initial cohorts described in the Nature paper have not been published. Whether the healthspan gains persist across multiple generations, or whether they come with hidden costs like tissue overgrowth or immune dysregulation, is unresolved. The mechanistic picture also has gaps. Researchers know that larger HA polymers correlate with reduced cancer and inflammation in these mouse models, and they have identified p53 signaling as one pathway involved. But the precise chain of molecular events connecting bigger HA to better outcomes in living animals is still being mapped. Human HA metabolism differs from that of mice and naked mole rats, and no one has demonstrated that the same protective pathways would function identically in human tissues. There is also a nuance to the “10 times more” figure that is worth flagging. The order-of-magnitude difference in HA levels comes from tissue and plasma comparisons between naked mole rats and normal mice. In the transgenic animals, the increase varied by organ. Skin and brain showed particularly large jumps; other tissues responded less dramatically. The 10x number is a representative benchmark, not a uniform multiplier across every cell. One question readers may reasonably ask: do over-the-counter hyaluronan supplements offer any of these benefits? The short answer, based on current evidence, is no. Oral HA supplements contain molecules that are broken down during digestion and bear little resemblance to the very-high-molecular-mass forms produced by the nmrHas2 gene. The protection observed in these studies depends on HA being synthesized at the right size and in the right tissues, something a pill cannot replicate.What this research actually establishes
The strongest contribution of this body of work is identifying a clear biological target. Across four primary research papers spanning a decade, from the 2013 foundational discovery to the transgenic mouse and colitis experiments, the evidence consistently points to high-molecular-mass hyaluronan as a molecule with genuine anti-cancer and anti-inflammatory properties when present in sufficient quantities. Each of these is an original experimental study published in a peer-reviewed journal, not a review or opinion piece. If scientists can eventually find ways to safely boost high-molecular-mass HA production in human tissues, whether through gene therapy, drug compounds, or some other intervention, the mouse data suggest the payoff could be significant. But the distance between “suggest” in a mouse model and “prove” in human medicine typically spans years of additional research and clinical trials. For now, the naked mole rat has offered biology a compelling lead. Turning it into medicine is the work that lies ahead. More from Morning Overview*This article was researched with the help of AI, with human editors creating the final content.
